TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05245994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
Description: Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
Study: NCT05408572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010 (IL12-FHAB)
Description: SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010 (IL12-FHAB)
Description: SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010 (IL12-FHAB)
Description: SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
Study: NCT05117151

Intervention type: DIAGNOSTIC_TEST
Intervention: hypotension prediction index
Description: monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
Study: NCT00964951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
Study: NCT04901663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG
Description: Orally twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 MG; Amoxicillin 1000 MG
Description: Orally twice daily for 2 weeks
Study: NCT04918381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX System
Description: Nano-Pulse Stimulation (NPS)
Study: NCT01489501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical transplantation of CAOMECS to the ocular surface
Description: Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
Study: NCT05659914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib+durvalumab
Description: olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
Study: NCT04234347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous access method
Description: Comparing long and short axis approach to USGPIV access.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous access method
Description: Comparing long and short axis approach to USGPIV access.
Study: NCT05695040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary workshop proteins
Description: The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety.
Study: NCT04104854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
Study: NCT05934240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy group
Description: Manual therapy will be applied to the diaphragm and thoracic region.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham-manual therapy
Description: Sham-manual therapy will be applied to the diaphragm and thoracic region.
Study: NCT05808673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-change CMAB807X
Description: for subcutaneous injection only

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pre-change CMAB807X
Description: for subcutaneous injection only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: for subcutaneous injection only
Study: NCT06182176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine and Amodiaquine
Description: The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine and Amodiaquine
Description: The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
Study: NCT05340348

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples (36 mL) + fecal samples + hair sample
Description: Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
Study: NCT06005350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Nicotinamide-Riboside-Chloride Preparation 1000mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Preperation
Study: NCT06297577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)
Description: Albumin-PRF will be placed into intrabony defect
Study: NCT06291350

Intervention type: OTHER
Intervention: Plaque sampling and stool collection
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis

Intervention type: OTHER
Intervention: Plaque sampling and stool collection
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis

Intervention type: OTHER
Intervention: Plaque sampling and stool collection
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis

Intervention type: OTHER
Intervention: periodontal examination
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
Study: NCT05361382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flortaucipir radiopharmaceutical
Description: Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240 radiopharmaceutical
Description: MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)
Description: The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical.
Study: NCT05722366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active video game
Description: With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
Study: NCT04754269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage Intervention
Description: Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Intervention
Description: Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
Study: NCT05252286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video watching
Description: Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper group
Description: In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral education group
Description: the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
Study: NCT06297577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique (MIST)
Description: MIST will be the surgical access for treatment of Intrabony defect
Study: NCT06363695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Kenya
Description: Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Kenya
Description: Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual by Community Health Volunteers
Description: Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
Study: NCT05490316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI353 (Orismilast)
Description: dose 1 or dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI353 (Orismilast)
Description: dose 1 or dose 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06089031

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Function Test
Description: Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
Study: NCT06090955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Study: NCT05401539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardboard VR
Description: Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardboard VR
Description: Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
Study: NCT05869786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)
Description: In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
Study: NCT05795673

Intervention type: OTHER
Group type: OTHER
Intervention: Peer support program (intervention phase)
Description: Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints.
Study: NCT04887194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
Study: NCT05869786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: conventional rehabilitation program
Study: NCT04887194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: CYP2C9 probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: CYP2D6 probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: CYP3A4 probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: P-gp probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: BCRP probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor (PD-1) blocking antibody
Study: NCT05751265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study: NCT05339399

Intervention type: OTHER
Intervention: oxytocin augmentation
Description: Only observation of the outcome
Study: NCT05869786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation program
Description: conventional rehabilitation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
Study: NCT05272722

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG,
Description: Holter monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG,
Description: Holter monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG,
Description: Holter monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG,
Description: Holter monitoring
Study: NCT05764252

Intervention type: DEVICE
Intervention: BioEP
Description: All patient's EEG will have the BioEP score conducted on it